MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery

PharmFilm® shown effective in buccal delivery of Octreotide and Exenatide

Warren, N.J., October 13, 2015 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, recently presented on the Company's advancements in oral peptide drug delivery utilizing its PharmFilm technology at The Boulder Peptide Symposium, Boulder, CO, and Partnerships in Drug Delivery Conference 2015, Boston, MA,. Nozer Mehta Ph.D., MonoSol Rx Vice President of Biologics, was the presenter at both conferences.

The oral podium presentations, entitled "Advantages of Mucoadhesive Buccal Films for the Delivery of Peptides" and "Advantages of PharmFilm® Buccal Delivery Technology for Small Molecules and Peptides" highlighted the company's study of buccal peptide delivery with Exenatide and Octreotide. These chronic therapy drugs, like the majority of peptides, are traditionally delivered by injection.

Dr. Mehta commented, "MonoSol Rx's PharmFilm technology already boasts a number of technical advantages as a drug delivery technology. As we actively expand our development pathway to include peptide drugs to our pipeline, the findings from the early preclinical studies support the successful application of this technology for oral peptide delivery."

Keith Kendall, CEO of MonoSol Rx, also added "We are extremely encouraged by the progress MonoSol Rx has made on the small molecule and peptide delivery fronts. By providing patients a non-injectable alternative to everyday drugs using PharmFilm technology, we can develop more valuable and innovative products for patients and caregivers.  Through this work we further demonstrate that MonoSol Rx is a specialty pharmaceutical company at the forefront of research, development, and innovation."

MonoSol Rx currently has two commercialized oral film products: Suboxone® (Buprenorphine/Naloxone) for the treatment of opioid dependence and Zuplenz® (Ondansetron) for treatment of nausea and vomiting in patients receiving chemotherapy. The Company also has additional complex molecule product candidates currently in various stages of preclinical development.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients.  PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs.  The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals — Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence.  For press releases and other company information visit www.monosolrx.com.

About Exenatide

Exenatide is currently marketed as BYETTA, an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise.

About Octreotide

Octreotide, the active ingredient in Sandostatin® injection and Sandostatin® LAR Depot (octreotide acetate for injectable suspension), has been studied for over 20 years, and is approved for the treatment of acromegaly and carcinoid syndrome.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
  • This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Please complete our short form to speak with a business development specialist.